No Data
No Data
Bide Pharmaceutical (688073.SH) has repurchased 2.81% of its shares for a total cost of 99.99 million yuan.
On July 8th, Gelunhui reported that as of July 5, 2024, Bi De Pharmaceutics (688073.SH) used centralized bidding trading to repurchase a total of 2,554,024 shares of the company's stock, accounting for 2.8102% of the total share capital. The highest repurchase price was 52.99 yuan/share, the lowest price was 28.63 yuan/share, the average repurchase price was 39.15 yuan/share, and the total amount of funds paid was RMB 99,991,734.50 (excluding transaction fees). The company's repurchase amount has reached the lower limit of the repurchase funds in the repurchase program and has not exceeded the total repurchase funds.
Bide Pharmaceutical (688073.SH): Dai Lan accumulatively increased the shareholding of the company by 2.5572 million yuan.
On June 28, Gelunhui announced that Ms. Dai Lan has accumulated 70,090 shares of the company through the Shanghai Stock Exchange trading system by means of centralized bidding from January 24, 2024 to June 27, 2024. The shareholding accounts for 0.0771% of the total share capital of the company, and the total shareholding amount is RMB 2.5572 million (excluding transaction costs). It has exceeded the lower limit amount of RMB 2.5 million for this shareholding plan, and this shareholding plan has been fully implemented.
Bi De Pharmaceutical (688073.SH): Dinghua Yongchuang partners meeting reviewed and approved the resolution to dissolve and liquidate the partnership enterprise.
On June 18th, Gelunhui reported that Bidet Pharmaceuticals (688073.SH) recently received a notice from shareholder Dinghua Yongchuang to dissolve and liquidate the partnership enterprises at the Dinghua Yongchuang partner meetings. Dinghua Yongchuang will apply to the Shanghai branch of China Securities Depository and Clearing Corporation Limited for non-transaction equity transfer matters of its holding company's shares. After this change in equity, the number of shares held by relevant shareholders and concerted actors is 10,110,685 shares, and the proportion of the company's total share capital held decreased from 12.76% to 11.12%.
BeiDe Pharmaceutical (688073.SH) will distribute cash dividends for the year 2023 on June 26, with a dividend of 0.9 yuan per share.
BiDe Pharmaceutical (688073.SH) announced that it will issue the 2023 annual report on June 26, 2024...
Bide Pharmaceutical (688073.SH): Has repurchased 2.3426% of the company's shares.
On June 4th, Gelonhui reported that Bi De Pharmaceutical (688073.SH) has announced that as of May 31, 2024, the company has cumulatively repurchased 2,129,043 shares of the company through the Shanghai Stock Exchange trading system by means of centralized competitive bidding, accounting for 2.3426% of the total share capital of 90,882,948 shares. The highest repurchase price was 52.99 yuan/share and the lowest price was 31.01 yuan/share. The total amount of the transaction was 87,420,246.76 yuan (excluding transaction fees).
Bide Pharmaceutical (688073.SH): It sells such paraphthalic anhydride products
Gelonghui, May 9 | Bide Pharmaceutical (688073.SH) said on the investor interactive platform that the company sells such paraphthalic anhydride products.
No Data